Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1982 1
1984 2
1985 1
1987 3
1988 5
1989 5
1990 2
1992 1
1993 4
1994 8
1995 2
1996 6
1998 5
1999 4
2000 5
2001 4
2002 2
2003 4
2004 2
2005 2
2006 2
2007 4
2008 2
2009 1
2010 2
2011 1
2013 1
2014 1
2015 2
2016 1
2019 1
2020 1
2021 1
2022 0
Text availability
Article attribute
Article type
Publication date

Search Results

84 results
Results by year
Filters applied: . Clear all
Page 1
Platelet immunoregulatory factors.
Tykocinski ML, Xiong N, Morrow DM. Tykocinski ML, et al. Stem Cells. 1996;14 Suppl 1:240-5. doi: 10.1002/stem.5530140731. Stem Cells. 1996. PMID: 11012227 Free article. Review.
Virchow at 200 and Lown at 100 - Physicians as Activists.
Mangione S, Tykocinski ML. Mangione S, et al. Among authors: tykocinski ml. N Engl J Med. 2021 Jul 22;385(4):291-293. doi: 10.1056/NEJMp2103050. Epub 2021 Jul 17. N Engl J Med. 2021. PMID: 34279066 No abstract available.
Cell-surface engineering with GPI-anchored proteins.
Medof ME, Nagarajan S, Tykocinski ML. Medof ME, et al. Among authors: tykocinski ml. FASEB J. 1996 Apr;10(5):574-86. doi: 10.1096/fasebj.10.5.8621057. FASEB J. 1996. PMID: 8621057 Review.
Fn14•TRAIL effectively inhibits hepatocellular carcinoma growth.
Aronin A, Amsili S, Prigozhina TB, Tzdaka K, Rachmilewitz J, Shani N, Tykocinski ML, Dranitzki Elhalel M. Aronin A, et al. Among authors: tykocinski ml. PLoS One. 2013 Oct 10;8(10):e77050. doi: 10.1371/journal.pone.0077050. eCollection 2013. PLoS One. 2013. PMID: 24130833 Free PMC article.
Toxicology and Pharmacokinetic Studies in Mice and Nonhuman Primates of the Nontoxic, Efficient, Targeted Hexameric FasL: CTLA4-FasL.
Makdasi E, Amsili S, Aronin A, Prigozhina TB, Tzdaka K, Gozlan YM, Ben Gigi-Tamir L, Sagiv JY, Shkedy F, Shani N, Tykocinski ML, Dranitzki Elhalel M. Makdasi E, et al. Among authors: tykocinski ml. Mol Cancer Ther. 2020 Feb;19(2):513-524. doi: 10.1158/1535-7163.MCT-19-0558. Epub 2019 Dec 23. Mol Cancer Ther. 2020. PMID: 31871267
CTLA-4. FasL induces alloantigen-specific hyporesponsiveness.
Elhalel MD, Huang JH, Schmidt W, Rachmilewitz J, Tykocinski ML. Elhalel MD, et al. Among authors: tykocinski ml. J Immunol. 2003 Jun 15;170(12):5842-50. doi: 10.4049/jimmunol.170.12.5842. J Immunol. 2003. PMID: 12794109 Free article.
Pathology as the enabler of human research.
Crawford JM, Tykocinski ML. Crawford JM, et al. Among authors: tykocinski ml. Lab Invest. 2005 Sep;85(9):1058-64. doi: 10.1038/labinvest.3700321. Lab Invest. 2005. PMID: 16056243
HuR Contributes to TRAIL Resistance by Restricting Death Receptor 4 Expression in Pancreatic Cancer Cells.
Romeo C, Weber MC, Zarei M, DeCicco D, Chand SN, Lobo AD, Winter JM, Sawicki JA, Sachs JN, Meisner-Kober N, Yeo CJ, Vadigepalli R, Tykocinski ML, Brody JR. Romeo C, et al. Among authors: tykocinski ml. Mol Cancer Res. 2016 Jul;14(7):599-611. doi: 10.1158/1541-7786.MCR-15-0448. Epub 2016 Apr 6. Mol Cancer Res. 2016. PMID: 27053682 Free PMC article.
84 results